A Nurse Led Triage System in the Ambulatory Cellular Immunotherapy Setting

Delivery of cellular immunotherapy (IMTX) in the ambulatory setting continues to evolve in an academic Comprehensive Cancer Center. A dedicated IMTX outpatient department (OPD) was opened in 2016 (patients treated=427), providing both FDA approved CAR T cell and phase l/ll immune effector cell treatments. Provision of care to acutely ill patients, ensuring early recognition of treatment related side effects, and triggering a prompt hospitalization when indicated, requires an intricate triage system.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 590 Source Type: research

Related Links:

I recently attended the 2020 Longevity Therapeutics conference in San Francisco. I presented on the work ongoing at Repair Biotechnologies, but as is usually the case the more important parts of the visit took place outside the bounds of the conference proper. Longevity Therapeutics is one of the four or five core conferences for the longevity industry, at which you'll meet many of the early participants - a mix of scientists, entrepreneurs, and investors, and patient advocates. As such, most of the conference goers have already seen my updates, or are otherwise aware of the Repair Biotechnologies programs aimed at thymic ...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs
Authors: Okan Cakir M, Kirca O, Gunduz S, Ozdogan M Abstract Infections in immunocompromised-neoplastic patients represent a severe complication. Among bacteria, Enterococcus species constitute a common causative pathogen of urinary tract infections (UTIs), especially among hospitalized patients with or without urinary tract carcinoma, related commonly to urinary tract abnormalities, urinary catheters or prolonged antibiotic treatment. Although enterococci have been considered more commonly as colonization bacteria in the intestine than virulent agents, they are frequently implicated in UTIs. The high incidence of ...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Hematological malignancies have long been at the forefront of the development of novel immune-based treatment strategies. The earliest successful efforts originated from the extensive body of work in the field of allogeneic hematopoietic stem cell transplantation. These efforts laid the foundation for the recent exciting era of cancer immunotherapy, which includes immune checkpoint blockade, personal neoantigen vaccines, and adoptive T cell transfer. At the heart of the specificity of these novel strategies is the recognition of target antigens presented by malignant cells to T cells. Here, we review the advances in system...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Early detection of neurotoxicity (NT) and prompt intervention in patients receiving cellular immunotherapy products is crucial. Guidance on the type of neurologic assessment to be conducted has only recently been established. Previously inconsistent and infrequent assessments varied from institution and depended upon individual nurses ’ clinical experience with NT.  “ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells” was published in 2018 and a plan for implementation of a standardized NT nursing assessment was needed at a Comprehensiv...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 586 Source Type: research
A Comprehensive Cancer Center (CCC) providing cellular immunotherapy treatments developed a standardized discharge process to ensure optimal continuity of care following immune effector cell (IEC) therapy. As utilization of IEC therapies increases, it is imperative to have an outlined comprehensive discharge plan to promote continuity of care, treatment-specific follow up, and ensure both patient and referring provider feel confident to assume follow-up care. Nurses are pivotal to this process development and implementation.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 585 Source Type: research
In 2016, a Comprehensive Cancer Center opened an ambulatory cellular immunotherapy clinic, partnered with an inpatient facility for hospitalization. The center provides FDA Approved CAR T Cell therapies as well investigational immune effector cell (IEC) products under Phase I/II clinical trials. To optimize patient care, a multidisciplinary workgroup developed IEC specific standard of care guidelines. These standards facilitate alignment of care between sites and promotes collaboration between nurses and providers to enhance patient outcomes.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 600 Source Type: research
Cellular immunotherapy is a rapidly progressing field in multiple myeloma (MM). Multiple clinical trials have reported impressive efficacy of B cell maturation antigen (BCMA) directed chimeric antigen receptor cell therapy (BCMA CART) in MM. While trials demonstrated a high response rate, the durable response rate is around 30%. Most patients lose their CART cells, and the disease relapses within the first year, suggesting an inhibition by the MM tumor microenvironment (TME). Therefore strategies to overcome this inhibition would represent a major advance in this field.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 333 Source Type: research
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was approved by the FDA in October 2017 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer. Since the CAR-T modified cells multiply and persist in the patient's bloodstream, they have the potential to protect the patient against recurrence.Beginning October 1, 2017, two new, unique ICD-10 procedure codes were assigned to CAR-T immunotherapy (XW033C3 for peripheral venous route and XW...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 486 Source Type: research
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was first approved by the FDA in October 2017 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer.Cytokine release syndrome is a known serious adverse event after CAR-T infusion which results in symptoms including fever, nausea, headache, and hypotension. Tocilizumab is an anti-IL-6 receptor antagonist approved for the treatment of CRS in CAR-T patients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 477 Source Type: research
More News: Academia | Biology | Cancer | Cancer & Oncology | Hematology | Immunotherapy | Nurses | Nursing | Transplants